CatalymFinancing roundCatalym raises US$150mGerman cancer specialist Catalym GmbH has raised US$150m to finance proof-of-concept studies. more ➔
Hearing lossSensorion achieves milestones in Phase II...French Sensorion SA has reported new efficacy endpoints data from SENS-401 in a Phase II study for the preservation of residual hearing loss. more ➔
Rentschler Biopharma SEProduction capacityRentschler doubles cGMP capacityIn the largest expansion in the company’s 150-year history, the Laupheim-headquartered CDMO Rentschler Biopharma SE has launched a new production line at its site in Milford, USA. more ➔
Series A financingSciRhom GmbH closes €63m Series A financ...German iRhom2-targeted antibody specialist SciRhom GmbH has closed an oversubscribed €63m Series A financing that will be used to provide clinical proof of concept in autoimmune disorders. more ➔
AcquisitionLigand Pharma to acquire Apeiron BiologicsAustrian Apeiron Biologics goes to Ligand Pharmaceuticals for US$100m. more ➔
PartnershipEuroscreenFast and GW Vitek announce distr...Belgium-headquarted GCPR-screening specialist EuroscreenFast and Asian distributor GW Vitek have inked a strategic collaboration. more ➔
EMAEMA-Gate: PharmaMar wins suit against EMAThe European Commission has fully upheld the complaint by PharmaMar SA due to conflicts of interest of leading EMA experts in the (non-)authorisation of Aplidin. more ➔
Financing roundNovo Holdings and Abingworth co-lead £90m...Danish Novo Holdings A/S and Abingworth co-led the largest European Series A financing round this year. Together with existing and new investors, they put £90m into cancer ADC specialist Myricx Bio … more ➔
AcquisitionAnacura aquires Ohmx.bioMerger within Ghent, Belgium: Anacura acquires OHMX.bio (both residing in neighborhood), adding multi-omics for drug discovery and diagnostics to its services. more ➔
EMATen drug recommendations by EMA EMA’s human medicines committee (CHMP) recommended ten medicines for approval at its June 2024 meeting. more ➔
Catalym
Rentschler Biopharma SE
